This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
by Zacks Equity Research
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.
Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
by Arpita Dutt
Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.
Top Analyst Reports for Morgan Stanley, GM & Prudential
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Morgan Stanley (MS), General Motors (GM), and Prudential (PRU).
Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now
by Zacks Equity Research
Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.
Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.
Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
by Zacks Equity Research
How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?
Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study
by Zacks Equity Research
Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .
Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling
by Arpita Dutt
Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).
SanofiRegeneron Sarilumab Approved in Canada for Arthritis
by Zacks Equity Research
Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).
Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.
Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval
by Zacks Equity Research
Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.
Key FDA Events to Watch Out for in Q1
by Zacks Equity Research
Two important regulatory events scheduled in the first quarter of 2017.
Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases
by Zacks Equity Research
Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.
Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit
by Zacks Equity Research
Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.
The FDA Approved Fewer Drugs in 2016: Here's Why
by Arpita Dutt
Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?
Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.
Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent
by Zacks Equity Research
The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.
Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View
by Arpita Dutt
Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).
Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit
by Zacks Equity Research
Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.
Sanofi (SNY) Closes Business Exchange Deal with Boehringer
by Zacks Equity Research
Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
by Zacks Equity Research
On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).
Regeneron vs. Vertex: Which Stock is a Better Pick?
by Arpita Dutt
Both Regeneron (REGN) and Vertex look set for a rebound in 2017 after a tough and challenging 2016.